Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents.
Adult
Aged
Antiviral Agents
/ therapeutic use
Benzimidazoles
/ therapeutic use
Female
Ferritins
/ blood
Fluorenes
/ therapeutic use
Hepacivirus
/ isolation & purification
Hepatitis C, Chronic
/ blood
Hepcidins
/ blood
Humans
Iron
/ blood
Iron Overload
/ blood
Male
Middle Aged
Peptide Hormones
/ blood
Prospective Studies
Sofosbuvir
Uridine Monophosphate
/ analogs & derivatives
direct-acting antiviral agents
erythroferrone
ferritin
hepatitis C virus
hepcidin
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
15 Oct 2019
15 Oct 2019
Historique:
pubmed:
28
6
2019
medline:
7
1
2020
entrez:
28
6
2019
Statut:
ppublish
Résumé
Objective Hepcidin is a master iron regulator hormone produced by the liver, but precise mechanism underlying its involvement in iron overload in hepatitis C virus (HCV) infection remains unclear. We investigated the serum hepcidin levels against iron overload before and after HCV eradication. Methods We prospectively investigated the iron metabolism characteristics in 24 patients with HCV genotype 1b infection before and after treatment. We also assessed the serum erythroferrone (ERFE) levels to investigate its association with iron metabolism changes. Patients were treated with Ledipasvir 90 mg and Sofosbuvir 400 mg once daily for 12 weeks and observed for 12 more weeks in order to evaluate their sustained virological response. Results Serum hepcidin levels at baseline were in the normal range, although serum ferritin levels were increased. After HCV eradication, both serum ferritin and hepcidin levels were significantly decreased at 24 weeks from baseline (p<0.001, p=0.006, respectively). However, the serum hepcidin-to-ferritin ratios were significantly increased (p<0.001). In addition, the serum ERFE levels were significantly decreased (p<0.001). Increases in the serum hepcidin-to-ferritin ratios were correlated with decreases in the serum ERFE levels (ρ=-0.422, p=0.039). Conclusion Serum hepcidin levels were relatively low against ferritin levels in HCV infection. However, after HCV eradication, the serum hepcidin-to-ferritin ratios were increased. These results indicate the improvement of inadequate hepcidin secretion against iron overload after HCV eradication. Downregulation of ERFE may have affected the improvement of iron metabolism.
Identifiants
pubmed: 31243222
doi: 10.2169/internalmedicine.2909-19
pmc: PMC6859405
doi:
Substances chimiques
Antiviral Agents
0
Benzimidazoles
0
Erfe protein, human
0
Fluorenes
0
HAMP protein, human
0
Hepcidins
0
Peptide Hormones
0
ledipasvir, sofosbuvir drug combination
0
Ferritins
9007-73-2
Iron
E1UOL152H7
Uridine Monophosphate
E2OU15WN0N
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2915-2922Références
Nat Genet. 2014 Jul;46(7):678-84
pubmed: 24880340
Free Radic Biol Med. 2003 Oct 1;35(7):826-32
pubmed: 14583347
J Hepatol. 2009 Nov;51(5):845-52
pubmed: 19729219
Haematologica. 2017 Feb;102(2):260-270
pubmed: 28143953
Blood. 2011 Apr 28;117(17):4425-33
pubmed: 21346250
Blood Cells Mol Dis. 2016 May;58:45-51
pubmed: 27067488
Hepatology. 2008 Nov;48(5):1420-9
pubmed: 18671304
Res Commun Mol Pathol Pharmacol. 2000;107(1-2):39-44
pubmed: 11334369
Am J Gastroenterol. 2001 Aug;96(8):2487-8
pubmed: 11513196
Hepatology. 2000 Apr;31(4):997-1004
pubmed: 10733558
Lab Invest. 1997 Mar;76(3):365-74
pubmed: 9121119
Curr Opin Hematol. 2015 May;22(3):199-205
pubmed: 25710710
J Gastroenterol Hepatol. 2017 Apr;32(4):864-869
pubmed: 27637864
J Gastroenterol Hepatol. 2014 Feb;29(2):387-94
pubmed: 23926964
Hepatology. 2012 Aug;56(2):492-500
pubmed: 22334511
BMC Cancer. 2008 Jun 09;8:167
pubmed: 18541040
Biosci Rep. 2017 Nov 29;37(6):null
pubmed: 29097483
Gastroenterology. 2008 Jan;134(1):226-38
pubmed: 18166355
Blood. 2017 Sep 7;130(10):1243-1246
pubmed: 28739636
Blood. 2006 Aug 15;108(4):1381-7
pubmed: 16621968
Kidney Int. 2010 Oct;78(8):769-73
pubmed: 20668427
Am J Physiol Regul Integr Comp Physiol. 2015 Feb 15;308(4):R330-5
pubmed: 25519735
Physiol Rev. 2013 Oct;93(4):1721-41
pubmed: 24137020
J Hepatol. 2008 Nov;49(5):702-10
pubmed: 18620776
Gastroenterology. 2006 Nov;131(5):1440-51
pubmed: 17101320
J Hepatol. 2016 Feb;64(2):505-515
pubmed: 26596411